Accepted Manuscript

Title: Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) α/γ agonist aleglitazar in attenuating TNF- α -mediated inflammation and insulin resistance in human adipocytes

Author: Marika Massaro Egeria Scoditti Mariangela Pellegrino Maria Annunziata Carluccio Nadia Calabriso Martin Wabitsch Carlo Storelli Matthew Wright Raffaele De Caterina

PII: \$1043-6618(16)30075-5

DOI: http://dx.doi.org/doi:10.1016/j.phrs.2016.02.027

Reference: YPHRS 3087

To appear in: Pharmacological Research

Received date: 26-1-2016 Revised date: 25-2-2016 Accepted date: 25-2-2016

Please cite this article as: Massaro Marika, Scoditti Egeria, Pellegrino Mariangela, Carluccio Maria Annunziata, Calabriso Nadia, Wabitsch Martin, Storelli Carlo, Wright Matthew, Caterina Raffaele De.Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)*rmalpha/rmgamma* agonist aleglitazar in attenuating TNF-*rmalpha*-mediated inflammation and insulin resistance in human adipocytes.*Pharmacological Research* http://dx.doi.org/10.1016/j.phrs.2016.02.027

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Massaro M. et al., page 1

Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist

aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human

adipocytes

Running title: Anti-inflammatory effects by dual PPPAR agonist aleglitazar

Marika Massaro¹, Egeria Scoditti¹, Mariangela Pellegrino^{1,2} Maria Annunziata Carluccio¹, Nadia

Calabriso¹, Martin Wabitsch³, Carlo Storelli², Matthew Wright⁴ and Raffaele De Caterina^{5,6}*

¹National Research Council (CNR) Institute of Clinical Physiology, Lecce, Italy

²Department of Biological and Environmental Science and Technology (DISTEBA), University of

Salento, Lecce, Italy

³Division of Pediatric Endocrinology, Diabetes and Obesity, Department of Pediatrics and

Adolescent Medicine, University of Ulm, Germany

⁴Roche Pharmaceuticals, Basel, Switzerland

⁵"G. d'Annunzio" University and Center of Excellence on Aging, Chieti, and

6"G. Monasterio" Foundation for Clinical Research, Pisa, Italy

*Corresponding author:

Institute of Cardiology, "G. d'Annunzio" University - Chieti C/o Ospedale SS. Annunziata

Via dei Vestini - 66013 Chieti, Italy;

phone: +39-0871-41512

FAX: +39-0871-402817

E-mail: rdecater@unich.it

Funding statement: This work was supported by a grant from Roche Pharmaceuticals, Basel,

Switzerland.

Download English Version:

https://daneshyari.com/en/article/5843129

Download Persian Version:

https://daneshyari.com/article/5843129

Daneshyari.com